Skip to main content

Dr Amy Flaxman

Dr Amy Flaxman
Senior Post-Doctoral Researcher
contact me by email

Institute: University of Oxford, UK

 

Biography

Dr Flaxman has always been interested in translational research. She has worked on both pre-clinical studies developing vaccines for outbreak pathogens, such as Ebola, and clinical trials for pre-erythrocytic Malaria (including a human challenge model) and outbreak pathogens, such as Ebola, and MERS and Ebola. During the COVID-19 pandemic, she worked on immune responses to the Oxford ChAdOx1-nCoV vaccine for SARS-CoV-2 currently in Phase III clinical trials. Dr Flaxman led the lab team carrying out antibody testing post vaccination. She was interested in the difference in antibody responses induced over time with different doses of vaccine, in different age groups and how this changes with administration of a booster vaccine. She now works at the Oxford Vaccine Group as a Senior Post-Doctoral Researcher. In this role, she leads the lab team delivereing clincal studies investigating enteric fever, including testing vaccine immunogenicity and efficacy using human challenge models. She is interested in immunological correlates of protection.

 

Key Publications

1. A. L. Flaxman, N. Marchevsky, D. Jenkin et al Reactogenicity and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet 2021.

2. M. N. Ramasamy, A. M. Minassian, K. J. Ewer, A. L Flaxman et al Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2020.

3. S. Sebastian, A. Flaxman, K.M. Cha et al. A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector. Vaccines 2020.

4. P. M. Folegatti, M. Bittaye, A. Flaxman et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet ID 2020

 

Web Links of Interest

https://www.paediatrics.ox.ac.uk/team/amy-flaxman

https://www.linkedin.com/in/amy-flaxman-b8791b9b/

 

Become a member now

Click below to find out how to become a member.

Register